DOCSLIB.ORG

178S ASMS Directory of Members DAVID AASERUD the Lubrizol

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
178S ASMS Directory of Members DAVID AASERUD the Lubrizol View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector 178S ASMS Directory of Members DAVID AASERUD SUZANNE ACKLOO WILLIAM ADAMS The Lubrizol Corporation MDS Sciex Philip Morris USA 29400 Lakeland Blvd. 71 Four Valley Drive RD&E/OC-T3W Wickliffe, OH 44092 Concord, ON L4K 4V8 Canada 615 Maury Street Tel: 440 347 4776 Tel: 905 660 9005 Richmond, VA 23224 [email protected] [email protected] Tel: 804 274 2093 [email protected] SUSAN ABBATIELLO EUREKA ACOLATSE University of Florida 7237 Causeway Dr. #3B GARY E. ADAMSON Department of Chemistry Indianapolis, IN 46214 Merck and Co. PO Box 117200 Tel: 317 433 4016 Merch Research Laboratories Gainesville, FL 32611 [email protected] P.O. Box 4 Tel: 352 392 0536 West Point, PA 19486 [email protected] CHRIS ADAMS Tel: 215 652 1174 Uppsala University [email protected] LARRY ABBEY Biological & Medical Mass Spec Waters Corporation Box 583, BMC JULIE ADAMSON 4026 Oak Crest Drive Uppsala, SE-751 23 Sweden University of Michigan Tucker, GA 30084 Tel: 46 18 471 5729 930 N. University Tel: 770 414 5089 [email protected] Ann Arbor, MI 48109-1055 [email protected] Tel: 734-763-6535 GREG ADAMS [email protected] FRANK S. ABBOTT Diosynth Biotechnology University of British Columbia 3000 Weston Parkway TOM ADDISON Faculty of Pharmaceutical Science Cary, NC 27513 Covance-11 2146 East Mall Tel: 919 388 5690 6002/11 Vancouver, BC V6T 1Z3 Canada [email protected] 3301 Kinsman Boulevard Tel: 604 822 2566 Madison, WI 53704-2523 [email protected] LUKE ADAMS Tel: 608 242 2639 University of Washington, Chemistry [email protected] FADI ABDI Box 351700 Applied Biosystems Seattle, WA 98195 TERRI ADDONA 500 Old Connecticut Path Tel: 206 543 7656 Broad Instritute Framingham, MA 01702 [email protected] 320 Charles Street Tel: 508 383 7921 Cambridge, MA 02141 [email protected] NIGEL G. ADAMS Tel: 617 324 1785 University of Georgia [email protected] SAMI ABDULLAH Dept. of Chemistry Theratechnologies Inc. Cedar Street ANTHONY ADEUYA 2310 Alfred Nobel Blvd Athens, GA 30602 Purdue University Saint-Laurent, QC H4S 2A4 Canada Tel: 706 542 3722 P.O. Box 5323 Tel: 514-336-7800 [email protected] Lafayette, IN 47903 [email protected] Tel: 765 420 7773 ROBERT A. ADAMS [email protected] PETER ABRAHAMSSON ARLS, Inc. Agilent technologies 3480 Tanbark Court, NE DEVI ADHIKARI Drakegatan 10 Atlanta, GA 30319 Washington State University Gothenburg, Västra Götaland 40123 Tel: 404 255 4817 Fulmer Hall - Chemistry Sweden [email protected] Pullman, WA 99164 Tel: +46703054818 Tel: 509-335-3058 [email protected] TERRY ADAMS [email protected] Shimadzu RINAT ABZALIMOV 4 Bird Hill Ct JOSHUA ADKINS University of Massachusetts at Amherst Timonium, MD 21093 Pacific NW National Lab 710 North Pleasant Street, LGRT 701 Tel: 410 381 1227 PO Box 999 MSIN K8-98 Chemistry Department [email protected] Richland, WA 99352-0999 Amherst, MA 01003 Tel: (509)376-2286 Tel: (413) 545-2888 TOM ADAMS [email protected] [email protected] Waters Corp 505 Remington Falls Ridge ARIE ADMON ANDREW ACHEAMPONG Canton, GA 30114 Technion - Israel Institute of Tech Allergan Pharmaceuticals Tel: 770-928-5757 Department of Biology 2525 Dupont Drive, RD-2B [email protected] Haifa, 32000 Israel Irvine, CA 92612 Tel: 972 48293407 Tel: 714 246 4950 [email protected] [email protected] ASMS Directory of Members 179S RUEDI AEBERSOLD BRIAN AGNEW IKE AJAGBA Swiss Federal Institute of Technology Molecular Probes, Inc. Phoenix S&T, Inc. ETH Honggerberg 29851 Willow Creek Road 107 Chesapeake Blvd., Suite 102 HPT E 78 Eugene, OR 97402 Elkton, Maryland 21921 Zurich, Europe CH-8093 Tel: 541 465 8300 Tel: 410-996-9735 SWITZERLAND [email protected] [email protected] Tel: 41 1 633 31 70 [email protected] MIKE AGUIAR SATOKO AKASHI McGill University Yokohama City University SARAH AEBERSOLD Zotique Racicot YCU, Grad. Sch. Integr. Sci. Zymo Genetics Montreal, QC H3L 3M7 Canada 1-7-29 Suehiro-cho, Tsurumi-ku 1201 Eastlake Ave East Tel: (514) 745 8983 Yokohama, Kanagawa, 230-0045 Japan Seattle, WA 98102 [email protected] Tel: 81 45 508 7217 Tel: 206 515 4973 [email protected] [email protected] RODRIGO AGUILERA University of Southern California JOCELYN AKER BEAT AEBI School of Pharmacy, PSC Room 306B University of Washington Forensic Chemistry & Toxicology 1985 Zonal Avenue 5226 22nd Ave NE 12 University of Berne Los Angeles, CA 90089-9121 Seattle, WA 98105 Buehlstrasse 20 Tel: 323.442.1782 Tel: 206-778-1501 Berne, CH-3012 Switzerland [email protected] [email protected] Tel: 41 316318411 [email protected] JINWOO AHN KRISTI D. AKERVIK Lexicon Genetics Inc. Thermo Finnigan STEVE AFENDIS 7 Patina Pines Place 355 River Oaks Parkway Eli Lilly and Company The Woodlands, TX 77381 San Jose, CA 95134 88-3-354, Mail Code 1533 Tel: 281-705-9513 Tel: 408 965 6000 Lilly Corporate Center [email protected] [email protected] Indianapolis, IN 46285 Tel: 317 651 1719 SEONGHEE AHN SHAHZAD AKHTAR [email protected] Korea Research Institute of Standards Fujisawa Research Institute of America and Sceince 1801 Maple Ave JEFFREY AGAR 1 Dorying-Dong, Yuseong-Gu Evanston, IL 60201 Brandeis University Daejeon, 305-340 South Korea Tel: 847-491-3192 415 South St Tel: +82-42-868-5652 [email protected] Chemistry MS 015 [email protected] Waltham, 024532728 ANNA AKRAMI Tel: 781-736-2425 MARTIN AHNOFF Amgen, Inc. [email protected] AstraZeneca R&D 1 Amgen Center Drive DPMK & Bioanalytical Chemistry 2270/1-1-B NATHALIE AGAR Pepparedsleden 1 Thousand Oaks, CA 91320 Montreal Neurological Institute Molndal, S-431 83 Sweden Tel: 805 447 0061 3801 University Tel: 463 1 776 1352 [email protected] Room BT 210 [email protected] Montreal, QC H3A 2B4 Canada ALEXANDER AKSENOV Tel: 514-398-1945 MAURO AIELLO University of Florida [email protected] Applied Biosystems/MDS Sciex PO BOX 117200 71 Four Valley Drive Gainesville, FL 32601-7200 GEORGE R. AGNES Concord, ON L4K 4V8 Canada Tel: 352 392-0536 Simon Fraser University [email protected] [email protected] 8888 University Drive, Department of Chemistry EDWARD AISAWA EDMOND AKUBUIRO Burnaby, BC V5A 1S6 Canada Agilent Technologies ITT Industries - K & M Electronics Tel: 604 291 4387 MS 53U-DG 11 Interstate Drive [email protected] 5301 Stevens Ave., POB 58059 West Springfield, MA 01095 Santa Clara, CA 95052-8059 Tel: 413-263-6212 BILL AGNEW Tel: 408 553 7718 [email protected] Apotex Research, Inc. [email protected] Bioalnalytical Lab MEHRAN ALAEE 440 Garyray Drive KONSTANTIN AIZIKOV Environment Canada Weston, ON M9L 1P7 Canada BUSM Mass Spectrometry Resource 867 Lakeshore Rd., PO Box 5050 Tel: 416 749 9300 715 Albany Street, R-806 P.O. Box 5050 [email protected] Boston, MA 02118 Burlington, ON L7R 4A6 Canada Tel: (617) 638-6760 Tel: 905 336 4752 [email protected] [email protected] 180S ASMS Directory of Members JEAN-FRANCOIS ALARY SUSAN R. ALDERSON YEAKUB ALI Applied Biosystems/MDS Sciex Eastman Chemical Company University of Louisville 71 Four Valley Drive B-150, PO Box 1972 Dept. of Pharmacology & Toxic. Concord, ON L4K 4V8 Canada Kingsport, TN 37662 Louisville, KY 40292 Tel: 905 660 9006 Tel: 423 229 6318 Tel: 502 852 5164 [email protected] [email protected] [email protected] ASHKAN ALAVI TANJA ALEBIC-KOLBAH JOHN ALIANTI IONICS Mass Spectrometry Group Inc. Neurocrine Biosciences Gilead Sciences 130 Bradwick Drive, Unit 8 12750 Torrey Bluff Drive, Apt. 78 4 University Place Concord, ON L4K1K8 Canada San Diego, CA 92130-4216 4811 University Dr Tel: 905-660-9477 Tel: 858 523 9196 Durham, NC 27707-3458 [email protected] [email protected] Tel: 919-294-7180 [email protected] JENNY ALBANESE ROBERT ALECIO MEDAREX Positive Probability Ltd ALEXANDER R. ALLAN Kiowa drive PO Box 7203, 829 Highsted Valley Forensic Alliance Ltd South Lake Tahoe, CA 96158 Kenmore F5 Culham Science Centre Tel: 5305775198 Sittingbourne, Kent ME9 0AB UK Abingdon [email protected] Tel: 01795 471165 Oxon, OX14 3ED UK [email protected] Tel: 44 1235551800 JEFFREY ALBERTS [email protected] Eli Lilly Company ANTHONY J. ALEXANDER Lilly Corporate Center DC#0714 Bristol Myers Squibb JOHN M. ALLAN Metabolism Pharm Research Institute Monsanto Co. Indianapolis, IN 46285 5 Research Parkway V1B Tel: 317-651-5887 Wallingford, CT 06492-7660 800 North Lindbergh Blvd. [email protected] Tel: 203 677 6333 St. Louis, MO 63167 [email protected] Tel: 314 694 8298 MARCUS A. ALBRIGHT [email protected] Agilent Technologies CARL ALEXANDER 8910 Purdue Road, Suite 480 Battelle LAURIE ALLAN Indianapolis, IN 46268 505 King Avenue Varian Tel: 847-944-6308 Columbus, OH 43201 2900 Briar Mill Trail, Apt. 304 [email protected] Tel: 614 424 5233 Raleigh, NC 27612 [email protected] Tel: 919 787 6540 JAIME ALCANTARA [email protected] BA Research Co. JAMES ALEXANDER 1290 Ellesmere Road Rohm and Haas Co. JEREMY ALLEGOOD Toronto, ON M1P 2X9 Canada 727 Norristown Rd, PO Box 904 Georgia Institute of Technology Tel: (416) 922-0012 Spring House, PA 19477 IBB 315 Ferst Dr. [email protected] Tel: 215-619-5226 Atlanta, GA 30332 [email protected] Tel: 404 385 2918 ARMANDO ALCARAZ [email protected] Lawrence Livermore Nat'l Lab MICHAEL S. ALEXANDER PO Box 808, L-178 BASI DAVID ALLEN 7000 East Avenue 3138 NE Rivergate, Bldg. 301-C Proteomic Research Services, Inc. Livermore, CA 94551 McMinnville, OR 97128 4401 Varsity Drive, Suite E Tel: 925 423 6889 Tel: 503 472 8882 Ann Arbor, MI 48108 [email protected] [email protected] Tel: 734-973-7914 [email protected] PETER ALDEN ABDULLAH H.
Load more

Recommended publications
  • Peter Mackenzie, His Life and Labours
    EV, OSEPH VAWSON PETER MACKENZIE HIS LIFE AND LABOURS " BY THE SAME AUTHOR. Jicst Puhlislied. (1) THE FACE OF A SOUL. A Story of Art and Life. Crown 8vo, cloth gilt, 6s. [Readers of "Peter Mackenzie: His Life and Labours," will be interested to know that in this story—though written three years ago, and before the author had any idea of be- coming his biographer—Mr. Mackenzie figures as a preacher, and (chaps, vi. and ix.) his style and manner are most \ividly reproduced.] — Scotsman. "An interesting tale. , . Well written, and embodies a good vein of thoughtfulness." Neivcasth Daily Leader. — " A wholesome and entertaining storj'." (2) TFIE SOUL OF THE SERMON (Including The Minister's Monday and the Personality of the Preacher). Third Edition, cloth gilt, is. net. Christian World. — "Most stimulating reading. Mr. Dawson is a prophet of his time. Methodist Times. —"We predict for Mr. Dawson a wider sphere in the literature of to-morrow." Methodist RecordcT. —" Essays from a gifted pen. New Age. — " Full of good things." LONDON: ^t ft^c olixixorn JU'cas, 26 PATERNOSTER SQUARE AND 211 GRAY's INN ROAD. FrC'ii a j\'i^'aih-e by G. Ridsdalc CUare. Cia/'ioii, Lo>ido7i. N. •/ i'YOA' ,,\RLF.S H KEi LV : PETER MACKENZIE HIS LIFE AND LABOURS Rev. JOSEPH DAWSON AUTHOR nF 'the face of a Soul." AND "tHE SOUL OF THE SERMON " ETC. FIFTH EDITION |i'onii0n CHARLES H. KELLY 2, CASTLE ST., CITY RD. ; AND 66, PATERNOSTER ROW, E.a i8g6 ^^ 01.. I 16 K 3 — PREFACE rpniS biography was begun on December 16, 1895, J- and completed on March 21, 1896,—a period of three months and five days.
    [Show full text]
  • Oral Presentation Disclosures
    Oral Presentation Disclosures Adler, Lenard – Alcobra Pharma, APSARD/Pond Foundation, Major League Baseball, Major League Baseball Players Association, National Football League, New York University School of Medicine, Novartis Bioventures, Shire Pharmaceuticals, Sunovion, SUNY Upstate, Theravance, US Department of Veterans Affairs Cooperative Studies Program Anton, Raymond – Abbvie, Alkermes, Eli Lilly, Ethypharm, Lundbeck, Pfizer, Sunpharma Baker, Ross – Otsuka Pharmaceutical Development & Commercialization, Inc. Baldwin, David – Lundbeck Beaver, Jessica – Targacept, Inc. Bencherif, Merouane – Targacept, Inc. Bertolino, Alessandro – F. Hoffmann-La Roche, Ltd. Bradshaw, Mark – Euthymics Bioscience, Neurovance, Inc. Burdick, Katherine – Dainippon Sumitomo Pharma Bymaster, Frank – Euthymics Bioscience, Neurovance, Inc. Calabrese, Joseph – Sunovion, Teva (Cephalon) Cantillon, Marc – Forest, Kyowa, Lilly, Merck, Pfizer, Reviva Caroff, Stanley – Sunovion Chen, Yinzhong – Takeda Development Center Americas, Inc. Chengappa, Roy – Pfizer, Inc. Childress, Ann – Abbott Laboratories, Bristol Myer Squibb, GlaxoSmithKline, Ironshore, Janssen (Ortho-McNeil), Johnson & Johnson PRD, Lilly, Neos Therapeutics, Neurovance Inc., NextWave, Novartis, Noven, Otsuka, Pfizer, Rhodes, Sepracor, Shionogi, Shire, Somerset, Sunovion, Theravance Christine, Mazzucco – Janssen Cohen, Lee – Astra-Zeneca Pharmaceuticals, Bristol-Myers Squibb, Cephalon, Inc., GlaxoSmithKline, National Institute of Mental Health, National Institute on Aging, Noven Pharmaceuticals, Ortho-McNeil
    [Show full text]
  • Beyond Borders Global Biotechnology Report 2009 “It Is Different This Time Because This Crisis Is Deep-Rooted, Systemic and Persistent
    For media use only Under embargo until 5:01 UK time on 5 May 2009 Beyond borders Global biotechnology report 2009 “It is different this time because this crisis is deep-rooted, systemic and persistent. But, in spite of that, the industry has been here before, in that biotech companies have overcome seemingly insurmountable challenges in the past, bucking trends and defying odds.“ Glen T. Giovannetti and Gautam Jaggi, Ernst & Young Global Biotechnology Center To our clients and friends As the shockwaves from the global financial crisis rippled across the emphasizes the need for partnering models that allow companies world economy in late 2008 and 2009, they left little untouched. the flexibility to evolve, while Samantha Du of Hutchison The reverberations leveled long-standing institutions, triggered MediPharma discusses how China can offer firms advantages that unprecedented policy responses and revealed new risks. For the address weaknesses in the Western business model. biotechnology industry, the impact of these turbulent times has But turbulent times can make the unimaginable possible, and deepened the divide between the sector’s haves and have-nots. sweeping disruptions have often redrawn maps, changed playing Many small-cap companies are scrambling to raise capital and fields and altered rules and regimes. In “Beyond business as contain spending, while a select few continue to attract favorable usual?” — our Global introduction article — we present four valuations from investors and strategic partners. paradigm-shifting trends that have the potential to reshape the A number of this year’s articles focus on the acute challenges healthcare landscape and create new opportunities: high-quality created by the funding crisis.
    [Show full text]
  • The History of Audley Family R
    This document has been produced for display on www.audleyfamilyhistory.com and www.audley.one-name.net Please feel free to distribute this document to others but please give credit to the website. This document should not be used for commercial gain Audley Family History Compiled for www.audleyfamilyhistory.com & www.audley.one-name.net Family R Audley of Capesthorne, Siddington & Kingsley, Cheshire; Llangollen, North Wales, Widnes, Lancashire & Ilkley, Yorkshire. Contents REVISIONS.......................................................................................................................................................................2 INTRODUCTION.............................................................................................................................................................2 POSSIBLE LINKS BETWEEN THE VARIOUS FAMILIES IN THIS FILE...........................................................2 SUMMARY FAMILY TREE............................................................................................................................................2 FAMILY 1.......................................................................................................................................................2 FAMILY 2.......................................................................................................................................................4 FAMILY 3.......................................................................................................................................................4
    [Show full text]
  • A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder
    Neuropsychopharmacology (2017) 42, 2567–2574 © 2017 American College of Neuropsychopharmacology. All rights reserved 0893-133X/17 www.neuropsychopharmacology.org A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder *,1,2 3,4 5 6 3 Sanjay J Mathew , Ralitza Gueorguieva , Cynthia Brandt , Maurizio Fava and Gerard Sanacora 1Mental Health Care Line, Michael E. DeBakey VA Medical Center, Houston, TX, USA; 2Menninger Department of Psychiatry & Behavioral Sciences, Baylor College of Medicine, Houston, TX, USA; 3Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA; 4 5 Department of Biostatistics, Yale School of Public Health, New Haven, CT, USA; Departments of Emergency Medicine and Anesthesiology, Yale 6 University School of Medicine, New Haven, CT, USA; Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA Riluzole is a glutamate-modulating agent with neuroprotective properties approved for use in amyotrophic lateral sclerosis. The efficacy and safety of riluzole vs placebo as an adjunct to antidepressant medication in outpatients with major depressive disorder (MDD) was examined in a 3-site, 8-week, randomized, double-blind, placebo-controlled, fixed-dose trial using a sequential parallel comparison design = comprised of two phases of 4 weeks. Patients with MDD in a current major depressive episode (N 104) with an inadequate response to either a prospective or a historical trial of an antidepressant medication were randomized in a 2 : 3 : 3 ratio to the treatment sequences of riluzole/riluzole, placebo/placebo, and placebo/riluzole, respectively. The primary outcome was change in depression severity, as assessed by the Montgomery-Åsberg Depression Rating Scale (MADRS).
    [Show full text]
  • Health Care Equity Capital Markets Review
    Minneapolis New York HEALTH CARE EQUITY CAPITAL MARKETS REVIEW Boston Chicago 2007 Year-End Review San Francisco Palo Alto Charlotte Piper Jaffray Equity Capital Markets London January 2008 Shanghai Since 1895. Member SIPC and FINRA THE PIPER JAFFRAY TEAM Chad Abraham Managing Director Head of Equity Capital Markets (612) 303-6274 Equity Capital Markets J. West Riggs Neil Riley Co-Head of Health Care Capital Markets Co-Head of Health Care Capital Markets (212) 284-9578 (612) 303-1601 Jessica Gould Jonathan Jewett Kevin Lander Michael Bassett Associate Analyst Analyst Analyst (212) 284-9346 (612) 303-6365 (612) 303-8432 (612) 303-6865 PIPEs / RDs Dave Stadinski Mark Spiegel Managing Director Principal Head of PIPEs / RDs PIPEs / RDs (212) 284-9572 (212) 284-9502 Chad Huber Jason Charpentier Associate Analyst (212) 284-9573 (212) 284-9501 1 TABLE OF CONTENTS Section I IPO Market Review Section II Healthcare IPO Market Update Section III Follow-On Market Overview Section IV Healthcare Follow-On Market Update Section V Healthcare PIPE and Registered Direct Market Update Section VI Piper Jaffray 2007 Healthcare Review Appendix A Biopharma IPO Market Conditions 2 SECTION III 2007 IPO Market Review IPO Market Review Historical Volume Number IPO by Year IPO Capital Raised by Year 250 $60 IPO activity in 2007 227 $50.7 $50 200 196 was the strongest 188 $44.5 180 $42.5 $39.9 since 2004, both in # $40 150 of deals and $’s raised $30 100 $17.7 76 $20 Capital Raised ($B) Raised Capital Number of IPOs Completed IPOs of Number 50 $10 0 $0 2003 2004 2005
    [Show full text]
  • Disclosures ASCP Annual Meeting FAIRMONT SCOTTSDALE PRINCESS MAY 30-JUNE 3, 2016
    Disclosures ASCP Annual Meeting FAIRMONT SCOTTSDALE PRINCESS MAY 30-JUNE 3, 2016 www.ASCPP.org The following presenters have something to disclose: Aaronson, Scott: Neuronetics, Research support, Consulting – Self; Sunovion, Speaker – Self; Otsuka/Lundbeck, Speaker – Self; Genomind, Scientific Advisory Board - Self Achtyes, Eric: Avanir, Research grant, travel - Self; Otsuka, Research grant, travel - Self; Janssen, Research grant, travel - Self; Vanguard Research Group, Research grant, travel, advisory board - Self Alphs, Larry: Janssen, Employee - Self; Johnson & Johnson, Stockholder - Self Althof, Stanley: Abbott, Research support or consulting fees - Self; Allergan, Research support or consulting fees - Self; Astellas, Research support or consulting fees - Self; Eli Lilly, Research support or consulting fees - Self; Evidera, Research support or consulting fees - Self; Ixchelsis, Research support or consulting fees - Self; Palatin Technologies, Inc, Research support or consulting fees - Self; Pfizer, Research support or consulting fees - Self; Promescent, Research support or consulting fees - Self; Sprout Pharmaceuticals, Research support or consulting fees - Self; S1 Biopharmaceuticals, Research support or consulting fees - Self; Strategic Science Technologies, Research support or consulting fees - Self; Trimel Pharmaceuticals, Inc, Research support or consulting fees - Self; Vyrix, Research support or consulting fees - Self Anton, Raymond: Lilly, Supporter of ACTIVE - Self; Lundbeck, Supporter of ACTIVE - Self; Abbvie, Supporter of
    [Show full text]
  • Office of Sponsored Rseearch Annual Report
    Appendix 1: Detail Awards by Sponsor Sponsor Name FY07 Award Federal National Institute of Heart, Lung, and Blood $48,571,652.00 National Cancer Institute $47,118,627.59 National Institute of Child Health and Human Development $36,021,503.00 National Institute of General Medicine Science $30,503,207.61 US Agency for International Development $28,518,210.00 National Institute of Allergy and Infectious Diseases $22,575,655.00 National Science Foundation - Research $21,973,962.00 US Department of Education $20,656,776.00 National Institute of Diabetes, Digestive and Kidney Diseases $20,467,967.52 National Center for Research Resources $17,703,399.00 National Institute of Mental Health-NIH $15,444,116.88 National Institute of Neurologic Disorders and Stroke $11,870,830.00 National Institute of Environmental Health Sciences $10,155,578.00 National Institute of Dental and Craniofacial Research $9,930,748.00 National Institute on Drug Abuse $6,597,641.39 National Institute on Alcohol Abuse and Alcoholism $6,322,584.08 National Institute of Arthritis Musculoskeletal Skin Disease $6,003,908.06 US Environmental Protection Agency - GRANTS $5,900,293.00 Centers for Disease Control $5,530,614.00 National Center for Chronic Disease Prev and Health Promo(CDC) $5,293,659.00 National Institute on Aging $4,160,868.00 National Center for Human Genome Research $4,112,635.00 US Department of Energy $3,777,324.00 US Army Medical Research $3,744,464.00 National Institute of Nursing Research $3,664,814.00 Bureau of Health Professions $3,612,953.91 Maternal and
    [Show full text]
  • Poster Session II the Effects of Targeted NMDA Receptor Interventions on Sociability December 7, 2010 5:30PM-7:30 PM in a Standardized Paradigm
    Neuropsychopharmacology (2010) 35, S188–S296 & 2010 Nature Publishing Group All rights reserved 0893-133X/10 S188 www.neuropsychopharmacology.org Poster Session II the effects of targeted NMDA receptor interventions on sociability December 7, 2010 5:30PM-7:30 PM in a standardized paradigm. Disclosure: S. Deutsch: None. J. Burket: None. L. Jacome: None. W. Cannon: None. A. Herndon: None. 1. D-cycloserine Improves the Impaired Sociability of the Balb/c Mouse Stephen Deutsch*, Jessica A. Burket, Luis Jacome, William R. Cannon, 2. Serotonin Systems and Modulation in Dopamine Transporter Amy L. Herndon (DAT)-Deficient Mice Meredith A. Fox*, Micaella G. Panessiti, F. Scott Hall, George Uhl, Eastern Virginia Medical School, Norfolk, VA Dennis Murphy Background: The genetically-inbred Balb/c mouse strain shows NIMH/NIH, Bethesda, MD evidence of impaired sociability in a standard paradigm and is hypersensitive to behavioral effects of MK-801 (dizocilpine), a Background: Serotonergic compounds, serotonin transporter noncompetitive NMDA receptor antagonist. Specifically, relative to depletion and serotonin receptor alterations alter baseline and/or 8 week-old male outbred Swiss-Webster mice, 8 week-old male Balb/c drug-induced phenotypes expressed by dopamine transporter (DAT)- mice show diminished locomotor activity and spend less time in the deficient mice, adding to abundant evidence for interactions between vicinity of an enclosed 4 week-old male ICR stimulus mouse in a serotonergic and dopaminergic systems. 5-minute period and, when allowed to interact freely with the stimulus Methods: We now report studies that confirm and extend evidence for mouse for 5 minutes, make fewer discrete episodes of social approach selective influences of pharmacological alterations in the serotonin system and show suppression of its locomotor activity.
    [Show full text]
  • C:\Myfiles\Website\Dph Rcp WIP
    2003 MASSACHUSETTS LOW - LEVEL RADIOACTIVE WASTE SURVEY REPORT MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH RADIATION CONTROL PROGRAM 90 WASHINGTON STREET DORCHESTER, MA 02121 617-427-2944 OCTOBER 2005 2003 MASSACHUSETTS LOW - LEVEL RADIOACTIVE WASTE SURVEY REPORT OCTOBER 2005 THE COMMONWEALTH OF MASSACHUSETTS MITT ROMNEY GOVERNOR KERRY HEALEY LIEUTENANT GOVERNOR EXECUTIVE OFFICE HEALTH AND HUMAN SERVICES TIMOTHY R. MURPHY SECRETARY DEPARTMENT OF PUBLIC HEALTH PAUL J. COTE, JR. COMMISSIONER CENTER FOR ENVIRONMENTAL HEALTH SUZANNE CONDON ASSOCIATE COMMISSIONER RADIATION CONTROL PROGRAM ROBERT WALKER DIRECTOR DATA ANALYSIS AND SURVEY REPORT LAYOUT: FREDERICK P. BARKER JR., P.E., RADIATION CONTROL OFFICER RADIATION CONTROL PROGRAM TABLE OF CONTENTS Page Preface........................................................................................................................................1 Chapter 1: Executive Summary...................................................................................................3 Chapter 2: 2003 LLRW Management Data Summary...............................................................13 Chapter 3: National Data............................................................................................................21 Chapter 4: Financial Data...........................................................................................................30 Appendix A.................................................................................................................................32 LIST OF
    [Show full text]
  • ELS-Tíðindi Apríl 2009
    26. árgangur 15. apríl 2009 Alþjóðlegar tákntölur Tákntölur1) í fremri dálki gilda eftir því sem við getur átt um birtingar er varða einkaleyfi og Útgefandi: Einkaleyfstofan hönnun. Tákntölur í aftari dálki eru notaðar varðandi Ábyrgðarmaður: Elín Ragnhildur Jónsdóttir birtingar vörumerkja. Ritstjóri: Bergný Jóna Sævarsdóttir Afgreiðsla: Engjateigi 3, 150 Reykjavík (11) (111) Framlagningarnr. eða nr. á veittu Sími: 580 9400, Bréfasími: 580 9401 einkaleyfi/Skráningarnúmer Afgreiðslutími: kl. 10-16 virka daga (13) Tegund skjals Heimasíða: www.els.is (15) (151) Skráningardagsetning Áskriftargjald: 3.000,- (156) Endurnýjunardagsetning Verð í lausasölu: kr. 300,- eintakið (21) (210) Umsóknarnúmer Rafræn útgáfa (22) (220) Umsóknardagsetning ISSN 1670-0104 (24) Gildisdagur (30) (300) Forgangsréttur (dags., land, ums.nr.) (41) Dags. þegar umsókn verður aðgengileg Efnisyfirlit almenningi (44) (442) Framlagningardags./Birtingardags Vörumerki (45) Útgáfudagur einkaleyfis (48) Einkaleyfi endurútgefið með breytingum Skráð landsbundin vörumerki ...................................... 3 (500) Ýmsar upplýsingar Alþjóðlegar vörumerkjaskráningar ............................ 15 (51) (511) Alþjóðaflokkur Breytingar í vörumerkjaskrá ...................................... 41 (54) (540) Heiti uppfinningar/Tilgreining hönnunar/ Takmarkanir ............................................................. 56 Vörumerki (55) (551) Mynd af hönnun/Félagamerki Breytt merki .............................................................. 56 (57) Ágrip Leiðrétting ...............................................................
    [Show full text]
  • Past Forward 27
    FORWARDFORWARD ISSUE No. 27 SPRING 2001 The Newsletter of Wigan Heritage Service FREE Who in 1991 would have predicted the the Heritage Service staff for success of Past Forward 10 years on? contributing to and supporting this The magazine has certainly come a very From the Editor venture over the years, as well as to all long way since its humble beginnings as of satisfaction from editing Past those involved in the actual printing and two A3 sheets – not even stapled Forward is the realisation that, were it production of the magazine. The result together! But such was the immediate not for the magazine, many readers is a very high quality and professional response that even by the second issue would probably never have actually put product – as this issue once again the size had doubled – and it was pen to paper to record their memories confirms – which is eagerly anticipated stapled together! These were indeed and reminiscences. There are too and read throughout the world. exciting days for a Heritage Service still many contributors and correspondents I often think, during the compilation in its infancy, for not only was Past to mention – although the names of old of Past Forward, how strange it is that Forward making great strides, but this faithfuls (I’m sure they won’t object to several distinct themes appear. In this was also the time of the opening of the my calling them that!) like Ernie issue, for example, two such themes History Shop – another big success Taberner, Harold Smith, Harold have manifested themselves, by story.
    [Show full text]